ZBTB33 (Kaiso) is a dual-specificity transcriptional regulator that binds both methylated CpG dinucleotides (5'-CGCG-3') and unmethylated consensus sequences (5'-CTGCNA-3') 1. As a primary function, ZBTB33 recruits the N-CoR repressor complex to promote histone deacetylation and repressive chrX formation, notably repressing Wnt pathway target genes and MMP7 expression [UniProt]. The protein mediates cell-cycle regulation through the cyclin D1/E1/RB1/E2F pathway, with cell-type-dependent effects on proliferation 2. ZBTB33 also regulates DNA methylation homeostasis by interacting with de novo methyltransferases DNMT3a/3b and protecting genic and enhancer regions from demethylation 3. Clinically, ZBTB33 mutations have emerged as novel drivers of clonal hematopoiesis (CH), with positive selection in aging blood cells 45. These mutations correlate with increased infection risk, mortality, and hematological malignancy susceptibility 4. In cancer, ZBTB33 overexpression associates with poor prognosis and metastatic potential 2. Additionally, ZBTB33 subcellular partitioning functionally links autophagy markers and immune microenvironment features to breast cancer survival 6, and participates in the ZNF131/ZBTB33/SMC4 oncogenic axis in hepatocellular carcinoma 7.